Chronic kidney disease (CKD) is a complex and multifactorial disease, and one of the most prevalent worldwide. Chronic kidney disease-mineral bone disorders (CKD-MBD) with biochemical and hormonal alterations are part of the complications associated with the progression of CKD. Pathophysiology of CKD-MBD focused on abnormalities in serum levels of several biomarkers (such as FGF-23, klotho, phosphate, calcium, vitamin D, and PTH) which are discussed in this review. We therefore examine the prognostic association between CKD-MBD and the increased risk for cardiovascular events, mortality, and CKD progression to end-stage kidney disease (ESKD). Lastly, we present specific treatments acting on CKD to prevent and treat the complications associated with secondary hyperparathyroidism (SHPT): control of hyperphosphatemia (with dietary restriction, intestinal phosphate binders, and adequate dialysis), the use of calcimimetic agents, vitamin D, and analogues, and the use of bisphosphonates or denosumab in patients with osteoporosis.

Hu, L., Napoletano, A., Provenzano, M., Garofalo, C., Bini, C., Comai, G., et al. (2022). Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23(20), 1-24 [10.3390/ijms232012223].

Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic

Hu, Lilio;Napoletano, Angelodaniele;Provenzano, Michele
;
Bini, Claudia;Comai, Giorgia;La Manna, Gaetano
2022

Abstract

Chronic kidney disease (CKD) is a complex and multifactorial disease, and one of the most prevalent worldwide. Chronic kidney disease-mineral bone disorders (CKD-MBD) with biochemical and hormonal alterations are part of the complications associated with the progression of CKD. Pathophysiology of CKD-MBD focused on abnormalities in serum levels of several biomarkers (such as FGF-23, klotho, phosphate, calcium, vitamin D, and PTH) which are discussed in this review. We therefore examine the prognostic association between CKD-MBD and the increased risk for cardiovascular events, mortality, and CKD progression to end-stage kidney disease (ESKD). Lastly, we present specific treatments acting on CKD to prevent and treat the complications associated with secondary hyperparathyroidism (SHPT): control of hyperphosphatemia (with dietary restriction, intestinal phosphate binders, and adequate dialysis), the use of calcimimetic agents, vitamin D, and analogues, and the use of bisphosphonates or denosumab in patients with osteoporosis.
2022
Hu, L., Napoletano, A., Provenzano, M., Garofalo, C., Bini, C., Comai, G., et al. (2022). Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23(20), 1-24 [10.3390/ijms232012223].
Hu, Lilio; Napoletano, Angelodaniele; Provenzano, Michele; Garofalo, Carlo; Bini, Claudia; Comai, Giorgia; La Manna, Gaetano
File in questo prodotto:
File Dimensione Formato  
ijms-23-12223.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 920.04 kB
Formato Adobe PDF
920.04 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/953040
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 27
social impact